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Summary Serogroup A meningococcus epidemics occurred in refugee populations in Zaire in August
1994. The paper analyses the public health impact of a mass vaccination campaign
implemented in a large refugee camp. We compared meningitis incidence rates from 2
similar camps. In Kibumba camp, vaccination was implemented early in the course of the
epidemic whilst in the control camp (Katale), vaccination was delayed. At a threshold of 15
cases per 100 000 population per week an immunization campaign was implemented.
Attack rates were 94 and 134 per 100 000 in Kibumba and Katale respectively over 2
months. In Kibumba, one week after crossing the threshold, 121 588 doses of vaccine were
administered covering 76% of all refugees. Vaccination may have prevented 68 cases (30%
of the expected cases). Despite its rapid institution and the high coverage achieved, the
vaccination campaign had a limited impact on morbidity due to meningitis. In the early
phase in refugee camps, the relative priorities of meningitis vaccination and case
management need to be better deﬁned.
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Introduction
Serogroup A meningococcus is the most frequent
cause of acute bacterial meningitis (ABM) epidemics
in Africa (Galazka 1982; Greenwood 1987; Moore
1992; Peltola 1983). This serogroup can cause severe
epidemics whose attack rates tend to be higher than
for other serogroups (Moore et al. 1990). While the
efﬁcacy of group A meningococcal vaccine was
proved (Erwa et al. 1973; Peltola et al. 1977;
Reingold et al. 1985), the immunity it confers is of
limited duration; in young children it lasts less than
3 years (Reingold et al. 1985) and protection is poor
in infants (Galazka 1982; Schwartz et al. 1989). For
these reasons, meningococcal vaccine has not been
added to routine childhood immunization pro-
grammes (Galazka 1982; Reingold et al., 1985;
Wright 1989).
Mass vaccination campaigns seem to be able to
curtail epidemics (Binkin & Band 1982; Cadoz
1984; Cochi et al. 1987; Greenwood 1984;
Mohammed & Zaruba 1981; Spiegel et al. 1993)
, C 1996 Blackwell Science Ltd 385and may be cost-effective (Cochi et al. 1987). How-
ever, to be effective, mass vaccination campaigns
need to start early in the course of the epidemic
(Cadoz 1984; Greenwood 1984). As ABM has
become endemic in most of Africa’s meningitis belt,
it is difﬁcult for public health practitioners to deter-
mine whether one is facing the start of an epidemic
or a ﬂuctuation of the usual baseline number of
cases. In Burkina Faso an incidence rate of 15 cases
per 100 000 population per week averaged over 2
consecutive weeks has been found to be of a high
positive predictive value regarding subsequent epi-
demics. This incidence rate was later used as a
threshold for declaring an epidemic in sub-Saharan
Africa (Moore et al. 1990b; 1992; WHO 1995)
although the authors of the initial study speciﬁed
that it should be evaluated in different settings
(Moore et al. 1992).
Displaced populations are at high risk for ABM
outbreaks, with serogroup A meningococcus as the
most frequent cause (Moore et al. 1990b). The
threshold of 15 cases per 100 000 people per week
averaged over 2 weeks was recommended as the
decisive criterion for declaring an epidemic and insti-
tuting an immunization programme among refugee
populations in camps. According to current recom-
mendations, mass vaccination campaigns should be
implemented within 4–8 weeks of an epidemic’s
onset in order to have an impact on its course
(Moore et al. 1990b). Data on epidemics in refugee
settings are scarce and health policy is based on data
taken from non-camp situations. Disease dynamics
and the impact of mass vaccination campaigns may
vary in refugee populations, whose living conditions
are usually characterized by overcrowding and low
sanitary standards. The paper describes meningo-
coccus A epidemics in two Rwandan refugee camps
in Zaire in August 1994 and analyses the public
health impact of the mass vaccination campaign
carried out in one of them.
Materials and methods
Setting
The refugee camps Kibumba and Katale were
formed after the massive inﬂux of displaced persons
(between 500 000 and 800 000) from Rwanda into
the Goma region, north-eastern Zaire, in mid-July
1994. The camps were located 30 km apart in the
mountainous Kivu lake area which has an average
annual rainfall of 1200&300 mm (Wills et al.
1986). A long dry season occurs between June and
August, another short one in January and February.
Even the dry seasons can be fairly wet; in 1994,
rainfall intensiﬁed from early August. The average
annual temperature is 19)C.
Both camps were extremely overcrowded: the
available surface area per person of less than 10 m
2
was far below the recommended minimum of 30 m
2
(UNHCR 1986). Housing conditions were extremely
precarious in both camps. Three epidemics occurred
between mid-July and mid-August 1994; cholera,
shigellosis and meningococcal A meningitis. Health
conditions (Table 1) among both camp populations
were comparable and very poor (Goma Epidemi-
ology Group 1995). Various aid agencies provided
hospital and outreach health services to the
refugees.
Table 1 Population characteristics in Kibumba and Katale camps, July and August 1994
Kibumba Katale
Population number at the end of July 180 000 80 000
Population less than 5 years of age (%) 17 17
Proportion of refugees who died during the ﬁrst 3 weeks of the camp existence (%) 7.38 . 3
Average crude mortality rate per 10 000 per day at mid-August 5.24 . 3
Malnutrition prevalence amongst children less than 5 years of age (%) 20.12 3 . 1
Available surface per person (m
2) below 10 below 10
Prevaccination attack rates per 100 000 (week 1 to 4) 43.34 1 . 1
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Population ﬁgures were estimated from aerial photo-
graphs taken in early August combined with popu-
lation counts in randomly chosen high and low
density areas. Population ﬁgures at the time were
180 000 in Kibumba and 80 000 in Katale. From
early September, a part of the refugees were progres-
sively moved from Kibumba to a new setting,
Kahindo. The number of refugees leaving Kibumba
was registered by the Ofﬁce of the UNHCR and
used to adjust Kibumba population ﬁgures. In Katale
the population increased after a late arrival of refu-
gees, giving a new estimate of 110 000 on 21 August
1994. The age distributions of both populations
were comparable.
Epidemiological surveillance and case deﬁnition
A surveillance system was established in both camps.
The case deﬁnition for computation of ABM inci-
dence was ‘all suspect cases admitted to the camp
hospitals with bacteriological conﬁrmation of men-
ingococcus in the cerebrospinal ﬂuid’. Cases were no
longer bacteriologically conﬁrmed during the ﬁnal 3
weeks in Kibumba. In order to compute incidence
for these weeks, the proportion of positives from
the previous 6 weeks (number of bacteriologically
conﬁrmed cases as a proportion of the submitted
cerebrospinal ﬂuid) was applied to the weekly
number of reported cases. Katale cerebrospinal ﬂuid
samples were submitted to either the Bioforce or the
Israeli hospital laboratories. Most samples from
Kibumba were submitted to Bioforce, only a few to
the Israeli hospital laboratory. The extrapolation
was based on the proportion of positives from the
Bioforce laboratory. The threshold for an ABM epi-
demic was set by the Goma Epidemiology Group
(1995)a t15 conﬁrmed meningitis cases per 100 000
per week for each refugee camp in the Goma region.
Case fatality rates (CFR) were determined with data
from the in-patient registration system instituted in
the camps. Deaths of patients with an admission
diagnosis of meningitis were registered as deaths
caused by meningitis, whether the cases were further
conﬁrmed or not. The CFR was thus estimated as
the number of deaths due to meningitis as a pro-
portion of the number of clinically suspected cases.
Laboratory tests
A lumbar puncture was performed on each clinically
suspected case (neck stiffness and fever). A latex
agglutination test for the identiﬁcation of meningo-
coccus A antigen or bacterial culture was performed
by either the Bioforce or Israeli hospital laboratories
to obtain conﬁrmation.
Case management
A single dose of chloramphenicol in oil intramuscu-
lar (Moore et al. 1990b; Wali et al. 1979) was given
for the treatment of all suspected and laboratory
conﬁrmed cases (3 g in adults and 50–100 mg/kg in
children). In both camps, home visitors were trained
to recognize the clinical signs of meningitis and held
responsible for active case detection and referral to
hospitals.
Kibumba vaccination campaign
The target population for the vaccination campaign
was deﬁned as all refugees over 6 months of age.
The objective was to vaccinate the entire target
population (176 000) within one week. The ﬁrst case
was detected on 28 July. Six vaccination posts were
set up between 17 and 19 August. The refugees were
informed by radio and by 150 home visitors. Each
vaccination post was staffed by 30 persons including
a team supervisor, staff to reconstitute the lyophil-
ized vaccine and prepare syringes, vaccinators,
persons to assist during the injection of children,
guards, and clerks to complete the vaccination cards
and to collect age-related data. A subcutaneous
injection of 0.5 ml meningococcal polysaccharide
(A+C) vaccine was administered in the deltoid
muscle region. The vaccination campaign took place
from 20 to 28 August.
Katale vaccination campaign
The ﬁrst case was detected on 1 August 1994.
Immunization was initially postponed as resources
were preferably allocated to other priorities. Further
delays followed due to vaccine shortage. Mass
vaccination ﬁnally took place between 8 and 22
September. The strategy applied was similar to that
in Kibumba.
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vaccination campaign
The public health impact of the vaccination cam-
paign was evaluated by estimating its operational
effectiveness. This was deﬁned as the number of
cases prevented as a proportion of the number of
expected cases over a follow-up period of 2 months.
In this way, the overall effectiveness of the campaign
could be quantitated. Field vaccine efﬁcacy was not
measured. We did not examine prevention of cases
in the long term, as the main objective of a mass
vaccination campaign in the emergency phase of a
refugee crisis is to control an ongoing epidemic. We
assumed that both camps were comparable, and
Katale refugee camp served as a control. We also
assumed that the number of cases prevented in
Katale during that period was negligible as the
vaccination campaign was implemented towards the
end of the epidemic curve. Weekly incidence rates
(WIR) and attack rates (cumulative incidence rates
over the entire epidemic period) were compared.
The number of expected cases in Kibumba was
estimated from the attack rates observed in Katale.
The number of cases prevented in Kibumba was
obtained by subtracting the number of observed
cases from the number of expected cases. The
number of deaths prevented was computed by
applying Kibumba CFR to the estimated number of
cases avoided. The number of ABM cases prevented




The meningitis epidemics started in both camps sim-
ultaneously (Figure 1). Prevaccination attack rates
were similar (Table 1) conﬁrming the com-
parable status of both camps. One hundred and
sixty-two cases were observed between 28 July and
25 September in Kibumba, and 137 between
1 August and 25 September in Katale, yielding attack
rates of 94.2 per 100 000 (60 days) and 133.7 per
100 000 (56 days) respectively. Meningococcus sero-
group A was responsible for all conﬁrmed cases.
The proportion of conﬁrmed cases amongst all
cerebrospinal ﬂuid samples submitted to the
Bioforce laboratory was 57% for Kibumba between
1 August and 11 September (141 positive cerebro-
spinal ﬂuids out of 247 submitted) and 59% for
Katale during the same period (48 positives out of
82). The epidemic alert threshold set for Goma
camps was crossed during the week of 8 August in
both camps (Table 2). The WIR at that time was
17.8 per 100 000 per week in Kibumba and 17.5 per
100 000 per week in Katale. The threshold recom-
mended by Moore et al.( 1990b) was crossed
the following week. Between 15 August and
4 September, the CFR was estimated to be 8%( 14
deaths in 182 clinically suspected cases) in Kibumba.
In Katale the corresponding computation yielded a



























Figure 1 Weekly incidence rates of
meningococcal A meningitis, cases
per 100 000 per week, Kibumba
(solid line) and Katale (dotted line)
refugee camps. From 25 July to 25
September 1994.
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From 20 to 28 August, one week after crossing the
threshold, 121 588 doses were administered in
Kibumba covering 75.9% of the camp population
according to a survey carried out on 30 August
(95%C I71.8–80.0%) (MSF-Belgium and Epicentre,
unpublished observations). In Katale, 112 354
doses of vaccine were administered between 8 and
22 September.
Operational effectiveness of the Kibumba
vaccination campaign
The attack rate in Kibumba was 39.5 per 100 000
less than that of Katale over approximately 2
months (95%C I12.8–66.2 per 100 000)( P = 0 . 002).
In Kibumba, 68 cases, representing 29.6%o f230
expected cases, may have been prevented. Thus,
10 000 doses of vaccine administered may have
prevented 5.6 cases, and the Kibumba vaccination
campaign may have avoided 5 deaths. The estimated
operational effectiveness was conﬁrmed using an
independent method of estimation based on work by
Pinner et al. (1992) (data not shown).
Discussion
Attack rates recorded in this study, 94 and 134 per
100 000 in Kibumba and Katale respectively over
2 months, resemble those found in other refugee
camp outbreaks. In Khmer refugee camps attack
rates of 130 per 100 000 over 4 months and of 80
per 100 000 over 3 months were observed in 1980
(Moore et al. 1990b). A meningitis epidemic in
endemic areas is deﬁned as an annual incidence rate
of at least 100 per 100 000 population (Moore et al.
1992). The Kibumba CFR (8%) is comparable to or
lower than that found during other epidemics in
refugee camps: 28% in Thailand in 1980 (Moore
et al. 1990b) and 12.8% in Sudan in 1988 (Boelaert
1988, unpublished observations). In developing
countries, CFR between 3.5 and 34% are described
during meningococcal meningitis epidemics (Binkin
& Band 1982; Bosmans et al. 1980; Cochi et al.
1987; Moore 1992; Peltola 1983; Tikhomirov 1987).
In comparing CFR and attack rates, case deﬁnitions
should be taken into account. Only bacteriologically
conﬁrmed cases were considered in Goma camps.
In Katale, the epidemic lasted for 2 months and its
incidence peak arose within 3 weeks from case 1.
Epidemics described in the meningitis belt usually
last for several months (Greenwood 1984) with a
peak within the ﬁrst 12 weeks (Moore et al. 1990b).
Several causes may be hypothesized to explain why
the peak in Katale was early. Shorter dynamics have
been reported at village scale where outbreaks have
lasted for 4–8 weeks (Greenwood 1987). Epidemio-
logical data analysis at the aggregate level of a
country reveals longer duration than that seen in
discrete populations. Secondly, overcrowding and
poor sanitary conditions favour the spread of
meningococcus (Greenwood 1984; Peltola 1983;
Table 2 Number of new cases per week and weekly incidence rates of meningococcal A meningitis in Kibumba and Katale







(per 100 000 population per week)
Kibumba Katale Kibumba Katale Kibumba Katale
25–31 July (week 1) 3 — 180 80 1.7 —
1–7 Aug. (week 2) 8 1 180 80 4.41 . 3
8 – 14 Aug. (week 3) 32 14 180 80 17.81 7 . 5
15–21 Aug. (week 4) 35 22 180 110 19.42 0 . 0
22–28 Aug. (week 5) 37 38 180 110 20.63 4 . 5
29 Aug.–4 Sept. (week 6) 32 29 172 110 18.62 6 . 4
5 – 11 Sept. (week 7) 5 13 166 110 3.01 1 . 8
12–18 Sept. (week 8) 8 12 160 110 5.01 0 . 9
19–25 Sept. (week 9) 2 8 150 110 1.37 . 3
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not have been susceptible due to previous vaccina-
tion although to our knowledge no mass vaccination
campaign was carried out in Rwanda during the pre-
ceding 3 years. Fourthly, perhaps the early peak was
due to the intensiﬁcation of rainfall in early August.
Indeed, spontaneous drops in incidence rates are
common at the onset of the rainy season in the
meningitis belt (Greenwood et al. 1984). However,
epidemics in the central African lake region do not
seem to corroborate this seasonal pattern (Cadoz
1984; Greenwood et al. 1984). Epidemics starting or
continuing during the rainy season were described in
Rwanda and Burundi (Bosmans et al. 1980; Vimont-
Vicary & Rogerie 1983; A. Sasse & F. Varaine
1992, unpublished observations). We may therefore
assume that low proportions of susceptibles or inten-
siﬁcation of rainfall are not valid explanations of
an early peak. It seems that the rapid transmission
of the epidemic in Katale is due to reproducible con-
ditions inherent in refugee camps: they should be
considered as discrete populations, with a higher
meningococcus transmissibility.
The Kibumba vaccination campaign was carried
out according to recommendations by Moore et al.
(1990b). Obtaining a coverage of 75.9% in less than
8 days would have been almost impossible. Results
show that an estimated 30% of expected cases may
have been prevented over 2 months (5.6 cases
avoided by 10 000 doses of vaccine administered).
The low operational effectiveness obtained by the
Kibumba campaign may be attributed to the com-
bined effects of fast transmission and lack of early
predictors for the epidemic. Moreover, vaccine ﬁeld
efﬁcacy may have been considerably lower than
expected in this severely malnourished population
(Moore 1992).
Discussions about public health strategies in
refugee camps must consider competing health prob-
lems and the phase in which a camp is evolving. The
68 cases of meningitis and 5 deaths possibly pre-
vented by the mass campaign in Kibumba need to be
compared to approximately 5400 preventable deaths
from diarrhoeal diseases (MSF-Belgium 1994,
unpublished observations) that occurred during the
same 2 months.
A sudden decrease in incidence subsequent to the
vaccination campaign was indeed observed in
Kibumba. Some previous reports attributed such
immediate decreases to preceding mass vaccination
campaigns (Binkin & Band 1982; Cochi et al. 1987;
Spiegel et al. 1993). But our data show that a syn-
chronous decline in incidence occurred in Katale
independently of any vaccination. This suggests that
the Kibumba campaign might not have been the only
factor responsible for the declining incidence rate in
this camp.
On the basis of these observations we conclude
that the current recommendations for meningitis A
epidemic control in refugee camps merit reconsider-
ation. Firstly, is the ‘Burkina Faso threshold’ valid in
a refugee camp? Moore et al.( 1992) concluded that
it may not be applicable in other settings. To
improve the potential beneﬁts of mass vaccination
campaigns, thresholds allowing for earlier action are
needed. A more sensitive threshold might still have a
sufﬁciently high positive predictive value, as the
probability for a meningococcal epidemic is higher in
a camp due to household crowding (Moore 1992;
Reingold et al. 1985; Schwartz 1989; Moore et al.
1990a), poor health status (Peltola 1983), low
nutritional status (Moore 1992), poor living con-
ditions (Peltola 1983) and mass migration of popu-
lations (Moore 1992; Schwartz 1989). Other
predictive factors should also be considered, such as
the presence of an epidemic in a neighbouring area
and the clonal type (Moore et al. 1989; Moore
1990a; Schwartz et al. 1989). Secondly, is it justiﬁed
to allow for 4–8 weeks from case 1 for completion
of a mass vaccination campaign, as the current
recommendation holds (Moore et al. 1990b)?
Would that not be too late to provide protective
levels of antibodies for the ongoing epidemic?
Special attention should be paid to the promptness
of the intervention and the coverage to be achieved.
However, the appropriateness of a mass vacci-
nation campaign in the emergency phase with high
overall mortality should be questioned. An alterna-
tive strategy under conditions with serious compet-
ing mortality risks might be active case detection and
early treatment. In untreated meningococcal disease
CFR can reach 50% (Galazka 1982) or more during
epidemics (Peltola 1983; Galazka 1982), whereas
early treatment can reduce CFR to less than 10%
(Galazka 1982; Cadoz 1984). Such a strategy also
prevents deaths from other causes.
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effectiveness of alternative strategies such as a joint
measles and meningitis vaccination upon arrival of
refugees in a camp. In the long term, a vaccine con-
ferring longer lasting immunity as part of routine
childhood immunization programmes would be the
best answer to some of the questions raised.
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